Scholar4AI Updated 2026-11-05 06:02 UTC+09:00

Kleijnen Systematic Reviews (United Kingdom)

Browse company research profiles

Papers in the tracked journals with an author at Kleijnen Systematic Reviews (United Kingdom): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education. Also as Markdown.

Share: X LinkedIn Bluesky Threads Facebook Reddit Hacker News Hatena LINE Email
Copy:

← Corporate research

Key findings#

  • From 2017 to 2026 (so far), authors at Kleijnen Systematic Reviews (United Kingdom) took part in 40 papers in the tracked journals, most of them in health economics and policy (38) and statistics (2).
  • 3 of them were published in 2025, against 6 in 2017.
  • Since 2023, the institutions with the most of these papers were Maastricht University Medical Centre (8), Care and Public Health Research Institute (4) and Erasmus University Rotterdam (4).
  • The journals publishing most of them were PharmacoEconomics (14).
  • The most-cited of them is “Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal” (PharmacoEconomics, 2017), with 32 citations.
  • Since 2023, papers in the tracked journals cited 13 of its papers 19 times; 89% of those links came from papers with a university author and 16% from its own papers.
  • Its own papers since 2023 cite archived papers 14 times, 36% of them papers with a company author.
  • Across everything OpenAlex indexes, Kleijnen Systematic Reviews (United Kingdom) has 360 works with 265,391 citations (h-index 124).
  • The tracked journals hold 36 of its 166 works in OpenAlex from 2017 to 2025 (21.7%).
  • Its main research topics in OpenAlex are Meta-analysis and systematic reviews (73), Health Systems, Economic Evaluations, Quality of Life (72) and Clinical practice guidelines implementation (35).

Papers per year#

2017: 6 papers2018: 7 papers2019: 4 papers2020: 4 papers2021: 2 papers2022: 3 papers2023: 5 papers2024: 2 papers2025: 3 papers2026 (so far): 4 papers
20172026 (so far)
Papers per publication year and category
Category2017201820192020202120222023202420252026 (so far)
Health Economics and Policy4744235234
Statistics2000000000
All categories6744235234

Where the papers come from#

Journals with the most papers, since 2023
#JournalPapers
1PharmacoEconomics14
Institutions with the most papers, since 2023
#InstitutionPapers
1Maastricht University Medical Centre8
2Care and Public Health Research Institute4
3Erasmus University Rotterdam4
4Maastricht University4
5Radboud University Medical Center4
6Radboud University Nijmegen3
7University Medical Center Groningen2
8University of Groningen2
9Isala1
Countries with the most papers, since 2023
#CountryPapers
1United Kingdom14
2Netherlands13
3Canada1
Keywords with the most papers, since 2023
#KeywordPapers
1cost-effectiveness10
2NICE single technology appraisal6
3NICE guidelines4
4NICE technology appraisal3
5health technology assessment3
6health-related quality of life3
7incremental cost-effectiveness ratio3
8cost comparison2
9economic modeling2
10indirect treatment comparison2

Most-cited papers#

Most-cited papers since 2017
#CitationsPer monthTitleJournalPublishedAuthors
1320.3Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPharmacoEconomics2017-06-27Nasuh Büyükkaramikli, Hedwig M. Blommestein, Rob Riemsma et al.
2260.3A Systematic Review of Direct Cardiovascular Event Costs: An International PerspectivePharmacoEconomics2019-04-04Steve Ryder, Kathleen M. Fox, Pratik P. Rane et al.
3190.2Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPharmacoEconomics2019-11-08Xavier Pouwels, Svenja Petersohn, Vanesa Huertas Carrera et al.
4180.2Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPharmacoEconomics2018-11-13Bram L. T. Ramaekers, Rob Riemsma, Sabine Elisabeth Grimm et al.
5160.2EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and UncertaintiesApplied Health Economics and Health Policy2018-05-28Rumona Dickson, Angela Boland, Rui V. Duarte et al.
6140.2Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox–Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPharmacoEconomics2020-06-09Ben F. M. Wijnen, Nigel Armstrong, Bram L. T. Ramaekers et al.
7130.1Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPharmacoEconomics2018-09-07Nasuh Büyükkaramikli, Saskia de Groot, Rob Riemsma et al.
8130.1Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPharmacoEconomics2018-10-06Sabine Elisabeth Grimm, Nigel Armstrong, Bram L. T. Ramaekers et al.
9110.1Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology AppraisalPharmacoEconomics2017-10-31Nasuh Büyükkaramikli, Saskia de Groot, Debra Fayter et al.
10110.1Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPharmacoEconomics2018-02-26Bram L. T. Ramaekers, Robert F. Wolff, Xavier Pouwels et al.

Who cites its research#

Institutions whose papers cite it most, since 2023
#InstitutionKindCountryLinks
1Maastricht University Medical CentreFunderNetherlands2
2University of SheffieldUniversityUnited Kingdom2
3Universidad Complutense de MadridUniversitySpain1
4Harvard UniversityUniversityUnited States1
5Radboud University NijmegenUniversityNetherlands1
6China Pharmaceutical UniversityUniversityChina1
7Carol Davila University of Medicine and PharmacyUniversityRomania1
8The University of MelbourneUniversityAustralia1
9Universidad de GranadaUniversitySpain1

What its papers cite#

Institutions its papers cite most, since 2023
#InstitutionKindCountryLinks
1Maastricht University Medical CentreFunderNetherlands3
2Maastricht UniversityUniversityNetherlands3
3Care and Public Health Research InstituteResearch facilityNetherlands3
4University of LiverpoolUniversityUnited Kingdom2
5National Institute for Health and Care ExcellenceGovernmentUnited Kingdom2
6Luxembourg Institute of HealthNonprofitLuxembourg2
7Zorginstituut NederlandFunderNetherlands2
8Novartis (United Kingdom)CompanyUnited Kingdom2
9University of YorkUniversityUnited Kingdom2

Citation links inside the tracked journals; see the corporate citation network and industry–university links.

In OpenAlex#

Kleijnen Systematic Reviews (United Kingdom) in OpenAlex
ItemValue
TypeCompany
LocationYork, England, United Kingdom
Also known asKSR
Works in OpenAlex360
Citations265,391
h-index124
i10-index570
2-year mean citedness3.08
Websitewww.systematic-reviews.com
RORror.org/004g82f36
OpenAlexopenalex.org/I4210088647
Main research topics (OpenAlex, all works)
#TopicFieldWorks
1Meta-analysis and systematic reviewsDecision Sciences73
2Health Systems, Economic Evaluations, Quality of LifeEconomics, Econometrics and Finance72
3Clinical practice guidelines implementationMedicine35
4Delphi Technique in ResearchSocial Sciences32
5Colorectal Cancer Treatments and StudiesMedicine24
Works and citations per year in OpenAlex, and its papers in the tracked journals
YearWorks in OpenAlexCitations receivedIn the tracked journalsShare
2026 (so far)177,133423.5%
2025119,073327.3%
20241810,096211.1%
20231510,322533.3%
20221711,656317.6%
20211115,451218.2%
20203112,842412.9%
2019218,742419.0%
2018196,832736.8%
2017235,936626.1%

From OpenAlex's own record of the institution (CC0), read again monthly. Works and citations count everything OpenAlex indexes, not only the tracked journals; topics are OpenAlex's classification of those works.

Cite this page

Scholar4AI. (2026). Kleijnen Systematic Reviews (United Kingdom). Journal and Conference Research Rankings. Retrieved November 5, 2026, from https://scholar4ai.com/companies/kleijnen-systematic-reviews-united-kingdom

@misc{scholar4ai-companies-kleijnen-systematic-reviews-united-kingdom,
  author = {{Scholar4AI}},
  title = {Kleijnen Systematic Reviews (United Kingdom)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/kleijnen-systematic-reviews-united-kingdom}},
  urldate = {2026-11-05},
  note = {Journal and Conference Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}

Free to reuse for non-commercial purposes with attribution (CC BY-NC 4.0).